News | Breast Imaging | April 04, 2017

Mercy Medical Center in Long Island Installs LumaGEM Molecular Breast Imaging System

New secondary screening method enables early cancer detection in women with dense breast tissue

Gamma Medica, LumaGEM molecular breast imaging system, MBI, Mercy Medical Center, Long Island, first New York install

April 4, 2017 — Gamma Medica announced in late March that Mercy Medical Center, a member of Catholic Health Services of Long Island, has purchased and installed New York’s first clinical LumaGEM Molecular Breast Imaging (MBI) system.

MBI is a secondary screening and diagnostic tool that is particularly useful for women who have dense breast tissue and women with a high risk of being diagnosed with cancer. It is a supplementary screening method to mammography, significantly increasing early detection in women who are at a higher risk due to dense breast tissue.

Approximately 50 percent of U.S. women are reported to have dense breast tissue. However, many women do not realize they have dense breasts or what it means for their increased risk of breast cancer. Because dense breast tissue and cancer both appear white on mammograms, cancer detection through mammography alone is difficult and may lead to false negatives or delayed diagnoses. Over 40,000 U.S. women die from breast cancer annually, making early detection imperative.

“The acquisition of the Molecular Breast Imaging system will better enable the detection of cancer to save lives,” said Mercy’s Executive Vice President and Chief Administrative Officer Ron Steimel. “This is just the latest milestone in Mercy’s longstanding dedication to the fight against cancer.”

While mammograms may fail to detect breast tumors due to tissue density, MBI highlights metabolic activity in these tumors despite breast density, leading to an earlier diagnosis. A retrospective clinical study published in the August 2016 issue of the American Journal of Roentgenology confirmed MBI’s high incremental cancer detection rate: MBI was able to detect 7.7 cancers per 1,000 women screened that were not found using mammography. Approximately 85 percent of these cancers were node negative, meaning they were detected at an earlier stage and presented a better prognosis.

“Mercy Medical Center is thrilled to add Gamma Medica’s LumaGEM to our suite of leading breast imaging technology,” said Conellia Ha, M.D., director of radiology at Mercy. “As a supplement to 3-D mammography, MBI will help us detect cancers in dense tissue that may have been missed by mammography alone. We feel confident that LumaGEM will support our mission to provide the best diagnostic care for our patients—the data behind MBI speaks for itself.”

For more information: www.gammamedica.com

Related Content

LOCalizer Implantable Tag Cleared for Long-Term Breast Lesion Placement
Technology | Breast Imaging | January 21, 2019
Hologic announced that the U.S. Food and Drug Administration (FDA) has cleared the LOCalizer radiofrequency...
Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
Opto-Acoustic Imaging Helps Differentiate Breast Cancer Molecular Subtypes
News | Ultrasound Women's Health | December 20, 2018
Seno Medical Instruments Inc. (Seno Medical) reported results of a study demonstrating that morphologic and functional...
Densitas Enters Platform Partnership With Blackford
News | Breast Density | December 19, 2018
Breast imaging analytics company Densitas Inc. announced the signing of a new Alliance Partner Agreement with Blackford...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...